Company intelligence / Profile preview
BioVie
- Ownership
- Public · BIVI
- Employees
- ~20
- Development stage
- Phase 2
Overview
BioVie is a clinical-stage biopharmaceutical company developing small molecule therapies targeting neurodegenerative diseases and advanced liver conditions. Its lead candidate, bezisterim (NE3107), has shown promise in reducing inflammation and improving insulin sensitivity in early studies. The company recently initiated a fully funded Phase II trial in Parkinson's disease with topline data expected late 2025 or early 2026. A once-daily formulation of NE3107 will be used in an upcoming Alzheimer's phase III trial. For refractory ascites due to liver cirrhosis, BIV201 demonstrated >50% reduction of fluid buildup among completers; the program awaits partnership funding before advancing to phase III.[5][6][8]
- Therapeutic areas
- GastroenterologyNeurology
- Modalities
- Small molecules (notably NE3107/bezisterim)[3][5][6]Peptide analogs (BIV201/terlipressin acetate)[3][4]
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $15.6M
- Total revenue
- $0
- Enterprise value
- $6.9M
Beyond the preview
Go deeper on BioVie.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioVie.